610 million doses of new coronal vaccine are here! Pricing by cost, not for profit

category:Finance
 610 million doses of new coronal vaccine are here! Pricing by cost, not for profit


In fact, price is also a matter of great concern to the public. In this regard, Zheng Zhongwei pointed out that the rumors on the Internet (the pricing of the new crown vaccine) are all false reports, and most of them are taken out of context. The pricing of new crown vaccine is not based on supply and demand, but on cost. The pricing of new crown vaccine must be within the scope of public acceptance.

By the end of the year, the production capacity could reach 610 million

Novel coronavirus pneumonia is a key task for the Chinese peoples health and Health Committee. We should fully understand the arduous and complex tasks of our countrys import and export prevention and internal defense rebound, and we should always tighten the string of epidemic prevention and control, overcome paralysis, slack mood, war weariness and relaxation mentality, strictly implement the measures of external input, and resolutely curb the spread of the new crown pneumonia epidemic in the mainland, and prevent the occurrence of the cluster epidemic.

Zheng Zhongwei said that novel coronavirus pneumonia is not occur even in a hundred years of global pandemic. Recently, in some countries and regions, there has been a new outbreak or rebound of the epidemic. For our country, it faces enormous new pressure of entering the epidemic.

In the process of coping with the pressure of overseas import and domestic rebound, some people in China have become high-risk exposed groups in the process of anti epidemic, such as the medical defense personnel on the front line of anti epidemic, the staff at border ports, the staff who have to go to high-risk countries or regions for work reasons to engage in assistance, and the public who maintain the basic operation of the city A total of service security personnel, they are facing the risk of infection. Therefore, it is very necessary to carry out the emergency use of vaccine among these people to protect their life, health and safety. Zheng Zhongwei said.

Zheng Zhongwei said that the emergency use of Chinas new crown vaccine is based on this, in strict accordance with the relevant provisions of the vaccine administration law of the peoples Republic of China and the drug administration law of the peoples Republic of China, and in accordance with the corresponding procedures. It has been strictly demonstrated and approved at all levels, and it also meets the relevant rules of the World Health Organization. After obtaining the approval for the emergency use of the new coronal vaccine in China, China also communicated with the representative office of the World Health Organization in China and obtained their approval and support.

Zheng Zhongwei recently introduced that in the process of promoting the emergency use of the new crown vaccine, China carried out a very strict expert demonstration and optimized the emergency use vaccine. Chinas emergency use of vaccines is strictly in accordance with the relevant provisions of all animal experiments and clinical phase I, II experiments, and phase I, II experiments have also achieved very good safety indicators and immunogenicity indicators. In addition, prior to the official launch of the emergency use of the new coronal vaccine, the preferred vaccine has been approved for three phases of clinical trials. At present, the large-scale population data of the third phase clinical trial in China once again verified the safety and effectiveness of the new crown vaccine emergency use in China.

While paying attention to the epidemic situation in China, China is also paying attention to the development of global epidemic situation, so that developing countries can also use and afford safe and effective vaccines.

Chinas China novel coronavirus pneumonia vaccine implementation plan has been launched by the World Federation of vaccines and immunization League of the world, Zhao Xing, a two level inspector of the Ministry of foreign affairs. It is also a new initiative for China to uphold the concept of the human health and health community and promote the vaccine to become a major global public product. And good reviews. The Chinese side has solemnly promised that after the research and development of Chinas vaccine is completed and put into use, it will give priority to providing it to developing countries as a global public product. This is also consistent with the goal and original intention of the implementation plan.

Zheng Zhongwei said that it is expected that by the end of this year, the annual production capacity of Chinas new crown vaccine will reach 610 million doses. Next year, the annual production capacity of Chinas new crown vaccine will be effectively expanded on this basis, so as to ensure the demand for Chinas new crown vaccine and other countries in the world.

The price is based on cost

With the approach of the full listing of the vaccine, the public is particularly concerned about whether the new crown vaccine can be included in the medical insurance and how to price it. Various versions of the price have also appeared on the Internet.

Novel coronavirus pneumonia vaccine was put forward by the NPC deputies.

In response to this proposal, not long ago, the State Medical Security Bureau released the reply to the recommendation No. 9354 of the third session of the 13th National Peoples Congress (hereinafter referred to as the reply) on its official website, saying that the financing level of basic medical insurance in China, especially for urban and rural residents, is relatively low. In 2019, the average financing of urban and rural residents medical insurance is only about 800 yuan, and the number of vaccinated people is large, The total cost is high, which is obviously beyond the affordability of medical insurance fund.

According to the vaccine management law of the peoples Republic of China implemented on December 1, 2019, vaccines in China are divided into immunization planning vaccine and non immunization planning vaccine. In July 2020, the Interim Measures for the administration of drug use in basic medical insurance clearly pointed out that: preventive vaccine is not included in the scope of medical insurance payment.

Previously, Liu Jingzhen, Secretary of the Party committee and chairman of sinopharma group, said in an interview with the media that after the completion of phase III international clinical trials, the new crown inactivated vaccine can enter the approval process, and is expected to be able to go on the market by the end of December this year. Moreover, he disclosed that after the inactivated vaccine is put on the market, the price will not be very high, and it is estimated that it will cost several hundred yuan per injection. If you take two injections, the price should be within 1000 yuan.

Not long ago, Yin Weidong, chairman, President and CEO of Kexing biology, also said that due to different purchasers and procurement scales, the price of vaccines would fluctuate to some extent, but the final price would be at the level of 100 yuan, not exceeding 1000 yuan.

Zheng Zhongwei said that the pricing versions circulated on the Internet are not true. For the price of Chinas new crown vaccine, first of all, it adheres to the pricing of enterprise entities, and at the same time, it adheres to several basic principles: one is the attribute principle of public goods, and the pricing must not be based on supply and demand, but on cost. The second is to carry out the pricing of new crown vaccine according to the publics willingness and demand for vaccination. Zheng Zhongwei said that the pricing of the new crown vaccine must be within the acceptable range of the public. He stressed that there are many factors that determine the price of new coronavirus vaccine, including cost, production capacity, vaccination scale, etc., and the costs of different technical routes are also different. For example, the production of inactivated vaccine requires a high-level biosafety workshop, and the cost is relatively high. The cost of vaccines such as adenovirus vector vaccine will be relatively low. With the expansion of production capacity and vaccination scale, the cost will also change. Source: editor in charge of economic report in the 21st century: Zhong Qiming_ NF5619

Zheng Zhongwei said that the pricing versions circulated on the Internet are not true. For the price of Chinas new crown vaccine, first of all, it adheres to the pricing of enterprise entities, and at the same time, it adheres to several basic principles: one is the attribute principle of public goods, and the pricing must not be based on supply and demand, but on cost. The second is to carry out the pricing of new crown vaccine according to the publics willingness and demand for vaccination.

Zheng Zhongwei said that the pricing of the new crown vaccine must be within the acceptable range of the public. He stressed that there are many factors that determine the price of new coronavirus vaccine, including cost, production capacity, vaccination scale, etc., and the costs of different technical routes are also different. For example, the production of inactivated vaccine requires a high-level biosafety workshop, and the cost is relatively high. The cost of vaccines such as adenovirus vector vaccine will be relatively low. With the expansion of production capacity and vaccination scale, the cost will also change.